Phase II Randomized Pilot Study of Pegaspargase vs Native E. coli Asparaginase in the Standard Treatment Arm of Protocol CCG-1952 for Standard-Risk Acute Lymphoblastic Leukemia
|Phase II||Treatment||Closed||1 to 9||NCI||CCG-1962|
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving drugs in different forms may cause fewer side effects in children with acute lymphoblastic leukemia.
- 1-9 years old
- No previous therapy for acute lymphoblastic leukemia
- At least 1 month since corticosteroids
- For more information about the eligibility criteria for this trial, refer to the Health Professional version.
Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Patients will be randomized to receive extended combination chemotherapy that includes either pegaspargase or asparaginase. Treatment may continue as long as benefit is shown, for up to 2 more years in girls and for up to 3 more years in boys. Patients will receive follow-up evaluations every 6-8 weeks for 1 year, every 3 months for 1 year, every 6 months for 1 year, and annually thereafter.
For more details about this trial, refer to the Health Professional version of the trial summary.
If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.
Trial Lead Organizations
Children's Cancer Group
|John Holcenberg, MD, Protocol chair|